California Bioequivalency Advisory
Selected Abstract
California Bioequivalency Advisory Panel finds "no evidence" to require change in standards for NTI medicines. (Narrow Therapeutic Index)(Generic RX Legislative Update)
On May 7, 1997, the California Bioequivalency Advisory Panel (BAP), chaired by Prof. Leslie Z. Benet, University of California San Francisco heard testimony prior to considering a number of questions related to Narrow Therapeutic Index (NTI) drugs. Among the key questions considered by the BAP was ... August 25, 1997; Chain Drug Review
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
California Bioequivalency Advisory Panel finds "no evidence" to require change in standards for NTI medicines. (Narrow Therapeutic Index)(Generic RX Legislative Update)
|
